Home / Business and Economy / Danish Theatre Stages Novo Nordisk's Rise to Power
Danish Theatre Stages Novo Nordisk's Rise to Power
30 Jan
Summary
- Play "The Golden Calf" chronicles Novo Nordisk's $200 billion rise.
- The company's evolution into a global behemoth is explored.
- Ethical questions surrounding drug production and patient health arise.
A new play titled "The Golden Calf" is set to premiere on Saturday outside Copenhagen, Denmark, chronicling the remarkable journey of Novo Nordisk. Founded in 1923 as Nordisk Insulinlaboratorium by the Danish couple August and Marie Krogh, the company has grown into a $200 billion pharmaceutical giant.
The production explores the company's transformation into a global leader, particularly through its influential GLP-1 drugs like Wegovy for weight loss and Ozempic for diabetes treatment. These medications have proven effective but raise complex ethical dilemmas.
"The Golden Calf" examines the core questions surrounding the company's motives: whether its primary goal is profit or aiding those in need. Director Nicolei Faber highlighted the play's focus on the founders and the subsequent "snowball" effect that led to Novo Nordisk's immense success, emphasizing the production was developed independently.
As Europe's former most valuable company, Novo Nordisk's growth trajectory has been immense, though it faces increasing competition. Recent challenges have led to plans for significant global job cuts, impacting thousands worldwide, including many in Denmark.
